TY - JOUR T1 - Hypercoagulation in COPD: the clot thickens JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00534-2021 VL - 7 IS - 4 SP - 00534-2021 AU - Farbod N. Rahaghi AU - Carrie L. Pistenmaa Y1 - 2021/10/01 UR - http://openres.ersjournals.com/content/7/4/00534-2021.abstract N2 - A number of studies have found systemic measures of thrombosis to be elevated in both stable COPD and during times of exacerbation [1–5]. The data is strongest for plasma fibrinogen, a US Food and Drug Administration-approved biomarker for drug development in COPD that predicts exacerbations and mortality [6, 7]. While the results have been inconsistent for the many other coagulation biomarkers studied, the cumulative (published) evidence points to abnormalities in the coagulation cascade in COPD. However, those with COPD also have an increased risk of cardiovascular disease and elevated inflammatory markers [8, 9], making these important potential confounders in any study of coagulation in COPD.There is a growing body of evidence that hypercoagulability is present in stable COPD, involves changes in multiple coagulation factors, and is not simply associated with major causes of inflammation and thrombosis https://bit.ly/3F5NnfN ER -